GSK Archives

Immunocore GSK Immuno oncology collaboration

News and Trends 8 May 2017

Immunocore Boosts its Collaboration with GSK with new Lead Compound

Immunocore has singled out a new lead candidate in its immuno-oncology discovery program with GSK, triggering an undisclosed milestone payment to Immunocore. Based in Oxford, Immunocore is one of the hottest biotechs in the immuno-oncology space, which was able to raise one of the largest European private funding rounds ever (€300M) and is backed by […]

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 3 Apr 2017

UPDATE: First Woman CEO of a Global Drug Maker starts at GSK today

GSK has punched a hole in the glass ceiling with its appointment of a new female CEO, Emma Walmsley. It’s up to her to reinvigorate the company. Emma Walmsley may be the most powerful woman in corporate Britain. The Oxford grad and L’Oreal veteran has just been crowned CEO of the pharma giant GSK: a marketing […]

April 3, 2017 - 2 minutesmins - By Evelyn Warner

Best in Biotech 8 Mar 2017

Which European Blockbusters Topped the Charts in 2016?

Blockbuster drugs are raking in billions each year in sales. Let’s have a look at the top 7 European best-seller drugs of 2016 and what their competition has to say. Not surprisingly, the top 3 best-selling drugs in Europe are biologicals, which are revolutionizing the treatment possibilities for a range of conditions, from cancer to chronic diseases. But with the increasing […]

March 8, 2017 - 4 minutesmins - By Melanie De Almeida

News and Trends 28 Feb 2017

It’s Global Rare Disease Day! What Cures is Biotech Cooking Up?

We’ve compiled a list of some of the latest advances of biotech in the field of rare disease to contribute to Rare Disease Day 2017. The European Organization for Rare Diseases (EURORDIS) is once again coordinating Rare Disease Day, which takes place on the last day of February every year. The aim is to raise awareness of […]

February 28, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

Apollo Therapeutics drug discovery launch

News and Trends 22 Feb 2017

UK’s Joint Venture Bridging Academia and Industry is Ready for Kick Off

Apollo Therapeutics is a UK-based joint venture bridging academia and industry to drive the translation of university research. Its first four drug discovery programmes will now be launched. Apollo Therapeutics was founded in early 2016 as a collaborative effort of the three global pharmaceutical companies, AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation, and the world-leading UK-universities, Imperial College London, UCL and the University of […]

February 22, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 14 Feb 2017

Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best

GSK announced Phase III results for dolutegravir, which could reduce triple HIV therapy down to two drugs, but Gilead is trying to prove that its candidate bictegravir is better. GSK and Gilead have announced they will present detailed data backing their candidates for a dual HIV therapy. The battlefield will be the Annual Conference on Retroviruses […]

February 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 5 Jan 2017

Investors Jump on Hypersensitivity Peptides from GSK Spinout

Neurokinins are under investigation for a range of conditions from women’s health to pain. NeRRe gets a boost for its programs. Neurotransmitting peptides just got a cash injection from Forbion, Fountain Healthcare Partners, Advent Life Sciences, Novo A/S, and Orbimed. NeRRe Therapeutics, a UK-based spinout of GSK, nailed down a €27M (£23M) Series B round. Helmed by […]

January 5, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 12 Dec 2016

French Biotech Puts a New Lyme Disease Vaccine on the Horizon

There is currently no vaccine for the fast-growing disease in the US, & treatments cost over $1Bn every year. Valneva might have a vaccine to stem the tide. Valneva, a commercial-stage biotech based in Lyon, France, has just received clearance from the FDA and its European counterpart to begin clinical trials for its experimental Lyme Disease […]

December 12, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 1 Dec 2016

UPDATE: The HIV Frontier starts Phase III Vaccine trials in South Africa

Update (01/12/2016): The HVTN 702 trial has been started, making it the first HIV vaccine efficacy study in 7 years worldwide. Results are expected in late 2020. Originally published 25/07/2016 A Phase IIb/III trial for an experimental HIV vaccine just started in South Africa. The therapy, co-funded by the NIH and the Gates Foundation, is a combination […]

December 1, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 30 Nov 2016

UPDATE: GSK is staging a comeback with a new Shingles Vaccine

GSK is banishing concerns about its health with a BLA submission for Shingrix, which has outperformed Merck’s standard and could bring GSK close to €1Bn. London-based GSK has just submitted a Biologics License Application to the FDA for its shingles vaccine candidate, Shingrix. Though it is still experimental, the vaccine is proving itself superior to the […]

November 30, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 7 Nov 2016

Results from 45% of Clinical Trials are kept Secret

A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […]

November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Sep 2016

GSK is Advancing a Revolutionary Dual HIV Therapy

Gilead has long been the leader in HIV treatments, but GlaxoSmithKline’s CEO revealed to the WSJ that the company has been investing in the field. It could give Gilead a run for its money with dolutegravir, a new integrase inhibitor so powerful it may knock the standard down from triple to dual therapy. Since the […]

September 1, 2016 - 3 minutesmins - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

GSK

Immunocore Boosts its Collaboration with GSK with new Lead Compound

UPDATE: First Woman CEO of a Global Drug Maker starts at GSK today

Which European Blockbusters Topped the Charts in 2016?

It’s Global Rare Disease Day! What Cures is Biotech Cooking Up?

UK’s Joint Venture Bridging Academia and Industry is Ready for Kick Off

Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best

Investors Jump on Hypersensitivity Peptides from GSK Spinout

French Biotech Puts a New Lyme Disease Vaccine on the Horizon

UPDATE: The HIV Frontier starts Phase III Vaccine trials in South Africa

UPDATE: GSK is staging a comeback with a new Shingles Vaccine

Results from 45% of Clinical Trials are kept Secret

GSK is Advancing a Revolutionary Dual HIV Therapy

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!